⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
FMO1 Inhibitors
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-07 — FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.: Preclinical chondrocyte/joint aging study: FMO1 elevated ROS and drove mitochondrial fission, p16/p21 senescence, and abnormal hypertrophy; genetic knockdown or pharmacological FMO1 inhibition (methimazole) blunted these phenotypes — seeds the mechanistic case for FMO1 as a chondrocyte-senescence target with no human outcome data. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
FMO1 disrupts mitochondrial functional homeostasis through ROS-mediated mechanisms to drive chondrocyte senescence and hypertrophy.
07-may-2026
novelty 3
per-area 3
strengthens